Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1260-1271
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Table 8 Changes in platelet counts in group C (15-21 d of treatment)
| Baseline | Day 5 | Day 9 | Day 14 | Post-treatment | Change | |
| n | 22 | 17 | 18 | 18 | 22 | 22 |
| mean ± SD (× 109/L) | 43.36 ± 19.23 | 47.47 ± 19.60 | 69.50 ± 33.25 | 107.61 ± 65.53 | 106.32 ± 65.97 | 62.95 ± 64.96 |
| Median (× 109/L) | 45.00 | 51.00 | 78.50 | 92.50 | 90.50 | 47.50 |
| IQR (× 109/L) | 27.75-59.25 | 31.00-54.50 | 32.50-85.75 | 55.25-181.25 | 55.25-148.00 | 16.5-128.25 |
| Min, max (× 109/L) | 10.00, 86.00 | 19.00, 95.00 | 20.00, 138.00 | 7.00, 235.00 | 7.00, 222.00 | -53.00, 179.00 |
- Citation: Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271
- URL: https://www.wjgnet.com/1948-9366/full/v14/i11/1260.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i11.1260